Cargando…
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
PRL3, a unique oncotarget, is specifically overexpressed in 80.6% of cancers. In 2003, we reported that PRL3 promotes cell migration, invasion, and metastasis. Herein, firstly, we show that PRL3 induces Polyploid Giant Cancer Cells (PGCCs) formation. PGCCs constitute stem cell-like pools to facilita...
Autores principales: | Thura, Min, Ye, Zu, Al-Aidaroos, Abdul Qader, Xiong, Qiancheng, Ong, Jun Yi, Gupta, Abhishek, Li, Jie, Guo, Ke, Ang, Koon Hwee, Zeng, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322210/ https://www.ncbi.nlm.nih.gov/pubmed/34326464 http://dx.doi.org/10.1038/s42003-021-02449-8 |
Ejemplares similares
-
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019) -
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021) -
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
por: Loh, Amos Hong Pheng, et al.
Publicado: (2023) -
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
por: Chee, Cheng E., et al.
Publicado: (2023)